A Trial to Test the Effects of Other Drugs on SEP‑380135 in Healthy Men and Women

Sponsor ID
384-201-00004
Clinicaltrials.gov ID
NCT07305779
EudraCT ID
N/A
EUCTIS ID
N/A
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information
N/A
Study Complete
Sponsor ID
384-201-00004
Trial Details
Subscribe for updates
Age
18 - 55 Years
Therapeutic Area
  • Schizophrenia
    • Sex
    Female & Male
    Trial Dates
    Mar 2025 - May 2025
    Healthy Volunteers
    Yes
    • Male or female participants between 18 and 55 years of age (inclusive) at time of consent
    • Body mass index from 18.0 to 32.0 kilograms per square meter (kg/m\^2) (inclusive).
    • In good health as determined by:
    • Medical history
    • Physical examination
    • Vital signs
    • Neurological examination
    • Electrocardiogram
    • Serum chemistry, lipid panel, thyroid panel, coagulation panel, urinalysis, hematology, and serology tests (from screening visit).
    • Willing to stay in the clinic for the required period (i.e., to be hospitalized for 10 days) and willing to be contacted for the safety follow-up telephone call.
    • Ability to provide written, informed consent prior to initiation of any trial-related procedures, and ability, in the opinion of the Principal Investigator, to comply with all the requirements of the trial.
    • Have taken an investigational drug within 30 days or 5 half-lives, if known, (whichever is longer) prior to screening.
    • Have had previous exposure to SEP-380135.
    • Are currently participating in another clinical trial.
    • Attempted suicide within 12 months prior to screening.
    • A history of sick sinus syndrome, first-, second-, or third-degree atrioventricular block, myocardial infarction, New York Heart Association Class II-IV heart failure, cardiomyopathy, pulmonary congestion, cardiac arrhythmia, prolonged QT interval, congenital long QT syndrome, family history of long QT, or moderate to severe hypokalemia. A participant with non-clinically significant ECG abnormalities at screening and check-in requires approval from the medical monitor and the sponsor's physician.
    • In the opinion of the investigator, should not participate in the trial.
    • Note: Other protocol-specified inclusion/exclusion criteria may apply.

    Study Summary

    The purpose of this study is to assess the effect of cytochrome P450 isoenzyme 2D6 (CYP2D6) inhibition by quinidine on the pharmacokinetic (PK) parameters of a single dose SEP-380135 in healthy adult participants.

    Additional Study Details

    Phase
    Phase 1
    Study Drug
    Drug: SEP-380135
    Type
    Interventional
    Masking
    None (Open Label)
    Estimated Enrollment
    12
    Additional Study Details

    Inclusion and Exclusion Criteria

    Inclusion Criteria

    • 1. Male or female participants between 18 and 55 years of age (inclusive) at time of consent
    • 2. Body mass index from 18.0 to 32.0 kilograms per square meter (kg/m\^2) (inclusive).

    Exclusion Criteria

    • 1. Have taken an investigational drug within 30 days or 5 half-lives, if known, (whichever is longer) prior to screening.
    • 2. Have had previous exposure to SEP-380135.
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    • Male or female participants between 18 and 55 years of age (inclusive) at time of consent
    • Body mass index from 18.0 to 32.0 kilograms per square meter (kg/m\^2) (inclusive).
    • In good health as determined by:
    • Medical history
    • Physical examination
    • Vital signs
    • Neurological examination
    • Electrocardiogram
    • Serum chemistry, lipid panel, thyroid panel, coagulation panel, urinalysis, hematology, and serology tests (from screening visit).
    • Willing to stay in the clinic for the required period (i.e., to be hospitalized for 10 days) and willing to be contacted for the safety follow-up telephone call.
    • Ability to provide written, informed consent prior to initiation of any trial-related procedures, and ability, in the opinion of the Principal Investigator, to comply with all the requirements of the trial.
    Exclusion Criteria:
    • Have taken an investigational drug within 30 days or 5 half-lives, if known, (whichever is longer) prior to screening.
    • Have had previous exposure to SEP-380135.
    • Are currently participating in another clinical trial.
    • Attempted suicide within 12 months prior to screening.
    • A history of sick sinus syndrome, first-, second-, or third-degree atrioventricular block, myocardial infarction, New York Heart Association Class II-IV heart failure, cardiomyopathy, pulmonary congestion, cardiac arrhythmia, prolonged QT interval, congenital long QT syndrome, family history of long QT, or moderate to severe hypokalemia. A participant with non-clinically significant ECG abnormalities at screening and check-in requires approval from the medical monitor and the sponsor's physician.
    • In the opinion of the investigator, should not participate in the trial.
    • Note: Other protocol-specified inclusion/exclusion criteria may apply.

    Locations

    Location
    Status
    Location
    Dr. Vince Clinical Research
    Overland Park, Kansas, United States, 66212
    Status
    N/A

    © 2026 Otsuka America Pharmaceutical, Inc.

    All rights reserved.

    January 2026 01US25EUC0489

    We defy limitation,

    so that others can too.

    Follow Us
    OAPI and OPDC Locations

    508 Carnegie Center Dr,

    Princeton, NJ 08540, United States

    Phone +1 609-524-6788

    2440 Research Blvd,

    Rockville, MD 20850, United States

    Phone +1 301-424-9055

    3956 Point Eden Way

    Hayward, CA 94545, United States

    Phone +1 800-562-3974